Rise of prediagnostic molecular profiling in inflammatory bowel disease-can we close the door before the horse has bolted?

Molecular features detectable years before symptoms can identify individuals at risk of developing IBD, offering a window for early intervention.

• Why it matters: Early detection of IBD is crucial to prevent disease progression and improve patient outcomes, but current diagnosis occurs only after symptoms appear, missing a potential preclinical phase.
• What they did: Analysis of archived biological samples from large longitudinal cohorts identified molecular markers such as antibodies and protein perturbations in healthy individuals who later develop IBD, highlighting early biological changes.
• The result: These findings enable the development of biomarker panels for preclinical detection, opening opportunities for proactive strategies to intercept IBD before clinical onset.